Treatment of Early Systemic Sclerosis by Bosentan

Phase 1

Terminated

• Conditions: Systemic Sclerosis (Scleroderma)

• Registration Number: NCT00226889
• Lead Sponsor: Rikshospitalet University Hospital

Brief Summary

Systemic sclerosis (ssc) is characterised by extensive tissue fibrosis. Using drugs that are capable of inhibiting fibroblast activity may be beneficial if administrered early in the disease course. Thirty adult patients with early SSc will be treated with the endothelin-1 antagonist bosentan for 6 months.Disease progression will be assessed.

Detailed Description

Systemic sclerosis (SSc) is characterised by obliterative vasculopathy and extensive fibrosis. The accumulation of extracellular components in the extracellular matrix is mostly due to increased activity og tissue fibroblasts. The proliferation and hyperactivity of the fibroblasts may be caused by enhanced production of several cytokins, among them endothelin-1.The activity of endothelin-1 has been shown to be increased both in the circulation and within skin lesions. Endothelin-1 has several distinct properties, among them profibrotic activity, inflammatory and vasoconstriction.Thus, the actions induced by endothelin-1 may be a potensial target for the therapy of SSc.

Thirty patients with early SSc, that is of less than 12 months duration will be offered six months of treatment with the oral dual endothelin-1 antagonist bosentan. Assessment of disease progression will be performed at 3, 6, 9. 12 and 24 months using clinical, histological and immunohistochemical methods.

Study Timeline

• Study Start: 2005-01
• Study First Submitted: 2005-09-23
• Study First Submitted QC: 2005-09-23
• Study First Posted: 2005-09-27
• Status Verified: 2006-03
• Primary Completion: 2009-01
• Study Completion: 2009-06
• Last Update Submitted: 2009-06-11
• Last Update Posted: 2009-06-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Early systemic sclerosis

Exclusion Criteria

• Age > 70 or < 18
• Pregnancy
• Nursing
• HIV
• Hb < 8.5 g/l
• Systolic blood pressure < 85 mmHg
• Lack of compliance
• Liver disease
• Hypersensitivity to bosentan
• Concurrent us of glibenclamide, ciclosporine A or tacrolimus -

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Overall clinical progression
Degree of deposition of ET-1 in skin

Secondary Outcome Measures

Name	Time	Method
Development of extradermatological manifestations
Quality of life

Trial Locations

Locations (1)

Department of rheumatology, Rikshospitalet; 🇳🇴 Oslo, Norway